Newsweek Ranks Karolinska University Hospital as the World’s 6th Best Hospital

With a nr six ranking, Karolinska University Hospital reaches its highest result yet in Newsweek Magazine’s ranking ”World´s Best Hospitals 2023”. Karolinska is ranked highest of all European hospitals.

Newsweek’s assessment encompasses more than 2 300 hospitals in 28 countries. The ranking is based on four aspects:

Recommendations from a large number of experts in the health care sector, such as physicians and managers. 80 000 experts globally were invited to participate, and a large number provided input.

Results from patient surveys, concerning e.g. patient communication and information

Quality results, such as waiting times, patient safety and hygiene compliance.
Use of patient reported outcome measures, meaning how patients themselves rate the effect of treatment on their health and function level.
Newsweek publishes both national ranking lists for all 28 countries and a list of the 250 best hospitals worldwide. After the last three years having reach number ten, seven and eight, Karolinska now takes a step up to number six globally and number one in Europe.

– This is a great acknowledgement for Karolinska’s staff and for Swedish health care, not least because the number of countries and hospitals included in the assessment has increased. We know we are among the best in the world and through Newsweek’s ranking the world is also finding out. After fighting the pandemic we have continued to cut waiting times, further improve quality and develop new treatment methods, says Björn Zoëga, CEO of Karolinska University Hospital.

28 countries are included in Newsweek’s ranking

USA, Germany, Japan, South Korea, France, Italy, Great Britain, Spain, Brazil, Canada, India, Australia, Mexico, The Netherlands, Austria, Thailand, Switzerland, Sweden, Belgium, Finland, Norway, Denmark, Israel, Singapore, Saudi Arabia, United Arab Emirates, Colombia and Taiwan.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version